

## Henry Schein Appoints Paul Brons to Board of Directors; Former Member of Akzo Nobel Board of Management Brings International and Pharmaceutical Experience

April 11, 2005

MELVILLE, N.Y.--(BUSINESS WIRE)--April 11, 2005--Henry Schein, Inc. (NASDAQ: HSIC), the largest distributor of healthcare products and services to office-based practitioners in the combined North American and European markets, today announced the appointment of Paul Brons to the Henry Schein Board of Directors. Mr. Brons is a former member of the Board of Management of Akzo Nobel NV, a leading manufacturer of diversified pharmaceutical, coatings and chemical products in over 75 countries.

As a member of the Akzo Nobel Board of Management for eight years, Mr. Brons led all of the company's pharmaceutical business units, including human and veterinary pharmaceuticals, OTCs, generics, diagnostics and pharmaceutical active ingredients. In addition to his pharma responsibilities, Mr. Brons also supervised Akzo Nobel's corporate purchasing, information technology and international business development; as well as the company's activities in China and Latin America. Prior to his tenure on the Board of Management, Mr. Brons served as President of Organon International BV, one of Akzo Nobel's pharma business units, for nine years, the culmination of a 29-year career with that company, which included several posts abroad.

"We are delighted to have a person of Paul's caliber join the Henry Schein Board of Directors," said Stanley M. Bergman, Chairman, Chief Executive Officer and President of Henry Schein. "Paul's wide-ranging international business experience and his expertise in pharmaceuticals have earned him a well-deserved reputation as one of Europe's premier pharmaceutical industry leaders. Our Board of Directors and management team look forward to the valuable contributions Paul will make to our company as we continue to expand internationally and add to our portfolio of pharmaceuticals, vaccines and other injectables."

While at Akzo Nobel, Mr. Brons contributed to the strengthening of the European Federation of Pharmaceutical Industry Associations (EFPIA), first as a member of its Strategic Advisory Committee, then as a member of their Board, and Chairman of EFPIA's EU Enlargement Committee. He was for many years actively involved in a worldwide policy group of CEOs from international R&D-based pharmaceutical companies, which sought to foster cooperation with governmental and non-governmental organizations. He also served as the European representative for the pharmaceutical industry at the Trans-Atlantic Business Dialogue, examining such issues as patent extension and AIDS in Africa.

Since retiring from the Akzo Nobel Board of Management in 2002, Mr. Brons has served on the Supervisory Boards for Akzo Nobel Netherlands and IBM Netherlands, as well as the Advisory Board for Barcelona-based Almirall Prodesfarma. A citizen of the Netherlands, Mr. Brons was honored in 1996 by Her Majesty the Queen with the decoration of Knight of the Order of Lion of the Kingdom of the Netherlands, the country's highest civilian order. This honor was conferred for his meritorious achievements for Akzo Nobel and for his many international activities.

"I am delighted to join a Board that includes so many distinguished directors," said Mr. Brons. "Before accepting this nomination, I had the opportunity to meet extensively with the senior leadership of Henry Schein and was impressed by the company's commitment to the highest standards of corporate conduct and the Team Schein culture that drives the organization. I hope to contribute to the continuation of Henry Schein's impressive growth for many years to come."

About Henry Schein, Inc.

Henry Schein, a Fortune 500(R) company, is recognized for its excellent customer service and highly competitive prices. The Company's four business groups - Dental, Medical, International and Technology - serve more than 475,000 customers worldwide, including dental practices and laboratories, physician practices and veterinary clinics, as well as government and other institutions. The Company's sales reached a record \$4.1 billion in 2004. The Company operates through a centralized and automated distribution network, which provides customers in more than 125 countries with a comprehensive selection of over 160,000 national and Henry Schein private-brand products.

Henry Schein also offers a wide range of innovative value-added practice solutions, including such leading practice management software systems as DENTRIX(R) and Easy Dental(R) for dental practices, and AVImark(R) for veterinary clinics, which are installed in over 50,000 practices; and Aruba(R), Henry Schein's electronic catalog and ordering system.

Headquartered in Melville, N.Y., Henry Schein employs more than 10,000 people in 19 countries. For more information, visit the Henry Schein Web site at [www.henryschein.com](http://www.henryschein.com).

CONTACT: Henry Schein, Inc.  
Steven Paladino, 631-843-5500  
[steven.paladino@henryschein.com](mailto:steven.paladino@henryschein.com)  
or  
Susan Vassallo, 631-843-5562  
[susan.vassallo@henryschein.com](mailto:susan.vassallo@henryschein.com)

SOURCE: Henry Schein, Inc.